Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

300%

3 of 1 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 2
5(83.3%)
Phase 1
1(16.7%)
6Total
Phase 2(5)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06663176Phase 1Active Not Recruiting

Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)

Role: lead

NCT07073638Phase 2Recruiting

Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis

Role: lead

NCT06041919Phase 2Terminated

Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis

Role: lead

NCT04858451Phase 2Terminated

COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2

Role: lead

NCT04842331Phase 2Withdrawn

PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)

Role: lead

NCT04460183Phase 2Completed

A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19

Role: lead

All 6 trials loaded